Information from “stalled” drug trials should be published, not tossed aside
Stephanie Sutton |
Only about one in 10 drugs that enter clinical development will make it past regulators. An analysis from researchers at McGill University has revealed that most trial data for drugs that don’t make the grade are never published (1).
The study examined drug trials in three areas – cancer, cardiovascular and neurological diseases – between 2005 and 2009. While 75 percent of clinical trials for approved drugs were published, this falls to 37 percent for drugs that reached Phase III clinical development, but were not approved within 4.5 years.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.